Table 6. Studies on combined laparoscopic cytoreductive surgery and HIPEC.

Studies	Patients (n)	Primary tumor	IP drugs	Morbidity	Hospital mortality	Follow-up
Esquivel et al. (62)	19	Appendix	Mitomycin	Grade 3: 0%; grade 4: 5% (internal hernia)	0%	17 months (mean); all NED
Van der Speeten (61)	1	Appendix	Mitomycin	0%	0%	9 years (NED)
Knutsen et al. (63)	5	Appendix (n=3), ileal carcinoma (n=1), galbladder (n=1)	Mitomycin	Grade 2: 20%	0%	12 months (median); 4/5: NED; 1: DOD
Hirano et al. (64)	11	Appendix	Mitomycin + cisplatin	2 renal dysfunctions, no further data	0%	22 months (median); 10: NED; 1: AWD
Esquivel et al. (65)	1	Mesothelioma	Cisplatin + doxorubicin	None	0%	6 months: NED
Passot et al. (66)	8	Appendix (n=5), mesothelioma (n=3)	Oxaliplatin (n=4), mitomycin + cisplatin (n=1), cisplatin + doxorubicin (n=3)	12.5%	0%	192 days (median), 8 NED
Fagotti et al. (67)	10	Recurrent ovarian cancer	Oxaliplatin (n=1), cisplatin (n=9)	0%	0%	10 months (median), 10 NED

HIPEC, hyperthermic perioperative chemotherapy; NED, no evidence of disease; DOD, dead of disease; AWD, alive with disease; IP, intraperitoneal.